Helsinn Healthcare S.A.: Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets

Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets* Lugano, Switzerland, and Singapore, 04 May 2022 - Juniper

Related Keywords

Qatar ,Australia ,Taiwan ,United States ,China ,Brunei ,Mauritius ,Tanzania ,Angola ,Coted Ivoire ,Sri Lanka ,Woman ,Bahrain ,New Zealand ,India ,Nigeria ,Egypt ,Cambodia ,Morocco ,Zimbabwe ,Kuwait ,Nepal ,Lugano ,Ticino ,Switzerland ,Libya ,Ireland ,South Korea ,Malaysia ,Japan ,Philippines ,Seychelles ,Algeria ,Lebanon ,Vietnam ,Republic Of ,Laos ,South Africa ,Indonesia ,United Arab Emirates ,Canada ,Jordan ,Pakistan ,Kenya ,Thailand ,Singapore ,Saudi Arabia ,Ivory Coast ,Twitterand Linkedin ,Kostenloser Wertpapierhandel ,Raman Singh ,Paola Bonvicini ,Helsinn Ceocommented ,Giorgio Calderari ,Gastroenterol Hepatol ,European Network For The Study Of Cholangiocarcinoma ,Linkedin ,Twitter ,Juniper Biologics Pte Ltd ,Drug Administration ,Helsinn Birex Pharmaceuticals Ltd ,Group Head Of Communication ,Therapeutics Goods Association ,Helsinn Group ,Health Canada ,Sylvan Group ,Juniper Biologicssignsexclusive ,Biologics Pte Ltd ,Southeast Asia ,Middle East ,Therapeutics Goods Association Approved ,Juniper Biologics ,Fully Integrated Targeted Therapy ,Important Safety Information ,Prescribing Information ,Helsinn Birex Pharmaceuticals ,Orphan Diseases ,European Network ,Nat Rev Gastroenterol Hepatol ,Rev Gastroenterol Hepatol ,Media Contact ,Biologics Contact ,Helsinn ,Healthcare ,Uniper ,Iologics ,Signs ,Exclusive ,License ,Agreement ,Infigratinib ,Merging ,Markets ,